Everolimus as primary immunosuppression in kidney transplantation: Experience in conversion from calcineurin inhibitors

Transplantation

Volumn 93, Issue 4, 2012, Pages 398-405

  Sánchez Fructuoso, Ana I ^a   Ruiz, Juan C ^b   Calvo, Natividad ^a   Rodrigo, Emilio ^b   Perez Flores, Isabel ^a   Gómez Alamillo, Carlos ^b   Fernández Pérez, Cristina ^a   Arias, Manuel ^b   Barrientos, Alberto ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Calcineurin inhibitors withdrawal; Everolimus; mTOR inhibitors; Nephrotoxicity; Proteinuria; Renal transplantation

Indexed keywords

EVEROLIMUS; TRIACYLGLYCEROL;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG DOSE INCREASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DYSFUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RASH; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; CALCINEURIN; COHORT STUDIES; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; PROTEINURIA; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; TREATMENT OUTCOME;

EID: 84857050988     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31823ffd0e     Document Type: Article

References (47)

1. Merville P. Combating chronic renal allograft dysfunction: Optimal immunosuppressive regimens. Drugs 2005; 65: 615.
2. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
3. Shirali AC, Bia MJ. Management of cardiovascular disease in renal transplant recipients. Clin J Am Soc Nephrol 2008; 3: 491.
4. Guba M, Graeb C, Jauch KW, et al. Pro-and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004; 77: 1777.
5. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581.
6. Mueller MA, Beutner F, Teupser D, et al. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/-mice despite severe hypercholesterolemia. Atherosclerosis 2008; 198: 39.
7. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
8. Mulay AV, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systematic review of the evidence. Transplantation 2006; 82: 1153.
9. Diekmann F, Campistol JM. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: Benefits and risks. Nephrol Dial Transplant 2006; 21: 562.
10. Wali RK, Mohanlal V, Ramos E, et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 2007; 7: 1572.
11. Kamar N, Frimat L, Blancho G, et al. Evaluation of the efficacy and safety of a slow conversion from calcineurin inhibitor-to sirolimusbased therapies in maintenance renal-transplant patients presenting with moderate renal insufficiency. Transpl Int 2007; 20: 128.
12. Liu M, Zhang W, Gu M, et al. Protective effects of sirolimus by attenuating connective tissue growth factor expression in human chronic allograft nephropathy. Transplant Proc 2007; 39: 1410.
13. Saber LT, Ikeda MY, Almeida JM. Posttransplantation conversion to sirolimus-based immunosuppression: A single center experience. Transplant Proc 2007; 39: 3098.
14. Diekmann F, Budde K, Slowinski T, et al. Conversion to sirolimus for chronic allograft dysfunction: Long-term results confirm predictive value of proteinuria. Transpl Int 2008; 21: 152.
15. Basu A, Falcone JL, Tan HP, et al. Chronic allograft nephropathy score before sirolimus rescue predicts allograft function in renal transplant patients. Transplant Proc 2007; 39: 94.
16. Sánchez Fructuoso A, Ruiz San Millán JC, Calvo N, et al. Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients. Transplant Proc 2007; 39: 2148.
17. Ruiz JC, Sánchez-Fructuoso A, Rodrigo E, et al. Conversion to everolimus in kidney transplant recipients: A safe and simple procedure. Transplant Proc 2006; 38: 2424.
18. Pape L, Ahlenstiel T, Ehrich JH, et al. Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A. Pediatr Transplant 2007; 11: 291.
19. Morales J, Fierro A, Benavente D, et al. Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: Effect on renal function and proteinuria. Transplant Proc 2007; 39: 591.
20. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481.
21. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36.
22. Schuurman HJ, Schuler W, Ringers J, et al. The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation. Transplant Proc 1998; 30: 2198.
23. Vitko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521.
24. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626.
25. Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 244.
26. Vigan ò M, Tuzcu M, Benza R, et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: A 24-month analysis. J Heart Lung Transplant 2007; 26: 584.
27. Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 1869.
28. Viklick ý O, Zou H, Müller V, et al. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000; 69: 497.
29. Lutz J, Zou H, Liu S, et al. Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation 2003; 76: 508.
30. Sedrani R, Cottens S, Kallen J, et al. Chemical modification of rapamycin: The discovery of SDZ RAD. Transplant Proc 1998; 30: 2192.
31. Salas-Prato M, Assalian A, Mehdi AZ, et al. Inhibition by rapamycin of PDGF-and bFGF-induced human tenon fibroblast proliferation in vitro. J Glaucoma 1996; 5: 54.
32. Azzola A, Havryk A, Chhajed P, et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004; 77: 275.
33. Ponticelli C. Can mTOR inhibitors reduce the risk of late kidney allograft failure? Transpl Int 2008; 21: 2.
34. Izzedine H, Brocheriou I, Frances C. Post-transplantation proteinuria and sirolimus. N Engl J Med 2005; 353: 2088.
35. Straathof-Galema L, Wetzels JF, Dijkman HB, et al. Sirolimus-associated heavy proteinuria in a renal transplant recipient: Evidence for a tubular mechanism. Am J Transplant 2006; 6: 429.
36. van den Akker JM, Wetzels JF, Hoitsma AJ. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int 2006; 70: 1355.
37. Senior PA, Paty BW, Cockfield SM, et al. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 2005; 5: 2318.
38. Aliabadi AZ, Pohanka E, Seebacher G, et al. Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. Am J Transplant 2008; 8: 854.
39. Butani L. Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 2004; 78: 1362.
40. Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: Mechanisms, significance, and management. Transplant Rev (Orlando) 2008; 22: 125.
41. Ruiz JC, Diekmann F, Campistol JM, et al. Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: A multicenter study. Transplant Proc 2005; 37: 3833.
42. Sennesael JJ, Bosmans JL, Bogers JP, et al. Conversion from cyclosporine to sirolimus in stable renal transplant recipients. Transplantation 2005; 80: 1578.
43. Boraty4 ń ska M, Banasik M, Watorek E, et al. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients. Transplant Proc 2006; 38: 101.
44. Liew A, Chiang GS, Vathsala A. Factors associated with proteinuria in renal transplant recipients treated with sirolimus. Transpl Int 2009; 22: 313.
45. Am H, Fidler ME, Myslak M, et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 2007; 7: 2748.
46. Vogelbacher R, Wittmann S, Braun A, et al. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007; 84: 1492.
47. Rangan GK. Sirolimus-associated proteinuria and renal dysfunction. Drug Saf 2006; 29: 1153.